Papilloedema, a complication of progressive diaphyseal dysplasia: a series of three case reports

Mark Wright, Neil R Miller, Robert M McFadzean, Paul Riordan-Eva, Andrew G Lee, Michael D Sanders, Gawn G McIlwaine

Abstract

Background/aims—Progressive diaphyseal dysplasia (PDD) is a rare, autosomal dominant, osteosclerotic dysplasia affecting both endochondrally and intramembranously derived bones. Severely affected patients can develop progressive stenosis of the optic canals and compressive optic neuropathy. Although raised intracranial pressure (ICP) has been described in patients with PDD in whom visual loss has occurred, the elevation of ICP in those patients has been thought to be either non-contributory or only partially responsible for the accompanying visual loss.

Methods—Three cases were reviewed and the clinical and radiological characteristics are described here.

Results—All three patients had bilateral optic disc swelling with no radiological evidence of either compressive optic neuropathy or thrombosis of the intracranial venous sinuses. The aetiology of the disc swelling was proved to be papilloedema in the first two cases and was probably the dominant cause in the third case.

Conclusion—The visual loss documented in at least two of the three patients reported appears to be solely attributable to raised ICP. Normalisation of the ICP has led to an improvement and stabilisation of the visual function in all three patients. Patients with PDD probably require periodic ophthalmic assessments.

(Br J Ophthalmol 1998;82:1042-1048)
Computed tomographic (CT) scanning of the brain and orbits demonstrated thickening of the skull consistent with PDD but with no associated stenosis of the optic canals (Fig 2). No dilatation of the ventricular system was noted. An intravenous digital subtraction angiogram showed no evidence of sagittal sinus thrombosis. At lumbar puncture, the opening pressure was elevated at 32 cm of water. Analysis of the cerebrospinal fluid (CSF) revealed no abnormalities.

A diagnosis of papilloedema was made but, as the patient had normal visual function, no treatment was given. Two months later, repeat kinetic perimetry demonstrated minimal bilateral peripheral visual field constriction with enlargement of the blind spots. The appearance of the optic discs was consistent with chronic papilloedema (Fig 3) and the patient was commenced on acetazolamide 250 mg four times daily. The disc swelling improved, and the dose was reduced to 250 mg twice over the subsequent 15 months.

In April 1991 the headaches returned and were accompanied by episodes of visual obscurations. The optic discs were more swollen; the visual fields were more constricted; and the dose of acetazolamide was increased to 250 mg three times daily with good effect. The serum alkaline phosphatase had risen concomitantly to 978 units/litre (normal value <260 U/l), suggesting that the clinical deterioration was related to an exacerbation of the bony dysplasia.

In June 1991 the patient complained of increasing deafness. Neuro-otological investigations demonstrated bilateral sensorineural hearing loss. Brainstem evoked potentials were abnormal, being absent on the left and of low amplitude and delayed on the right. A CT scan of the petrous temporal bones revealed bilaterally stenosed internal auditory canals and the patient therefore underwent decompression of the left vestibulocochlear nerve. At the last ophthalmic review in March 1997 visual acuity was 6/6 bilaterally, visual fields were full and there was no optic disc swelling, acetazolamide having been discontinued 6 months previously.

**CASE 2**

This 39 year old male was diagnosed as having PDD in 1963 at the age of 8 on the basis of characteristic radiological changes affecting the limbs (Fig 4) and skull.

Between 1980 and 1990, he suffered recurrent episodes of papilloedema which were not associated with a deterioration in visual function and which were treated with lumbar puncture.
Acetazolamide therapy had been withdrawn because of a drug induced rash and on at least one occasion the papilloedema spontaneously resolved. Systemic steroid therapy had also been withdrawn following a steroid induced osteoporotic stress fracture affecting the lumbar vertebrae in 1977.

He was referred to the Wilmer Eye Institute in Baltimore in June 1993 after the acute onset of blurring in the inferior aspect of the left visual field accompanied by visual obscurations in that eye.

On examination, the patient had the typical facial appearance associated with PDD (Fig 5). He also had fixed flexion deformities of the arms and legs and enlargement of the long bones. Visual acuity was 6/5 and N5 bilaterally, colour vision was normal, and no relative afferent pupillary defect was present. The visual field of the right eye showed enlargement of the blind spot with a supratemporal scotoma present. The left blind spot was sufficiently enlarged to encroach on fixation and was associated with a dense inferior arcuate scotoma. Both optic discs were swollen. A small peripapillary haemorrhage and an optociliary shunt were present in the right ocular fundus; an extensive circumferential peripapillary subretinal haemorrhage was present in the left fundus (Fig 6).

There was no evidence of stenosis of the optic canals or sagittal sinus thrombosis with CT scanning or magnetic resonance imaging (MRI). Orbital ultrasonography demonstrated enlargement of the optic nerves with a positive 30 degree test indicative of increased subarachnoid fluid. CT scanning and ultrasonography failed to demonstrate the presence of optic nerve head drusen. At lumbar puncture the opening pressure was 31 cm of water. Analysis
of the CSF gave normal results. Serum alkaline phosphatase was raised at 445 U/l.

Both optic discs became more swollen over the next 6 weeks, but the peripapillary haemorrhages and visual field defects improved.

At last review in December 1996, the optic disc swelling had spontaneously resolved (Fig 7) and spontaneous venous pulsations were present. Visual acuities were 6/5 right, 6/6 left, visual fields were full, with only minimal enlargement of the blind spots.

CASE 3
This 56 year old female first presented in 1946 at age 5 years with a painful gait, secondary muscle atrophy, and radiological changes of the skull and long bones which were typical of PDD. At age 16 years, she presented with bilateral progressive proptosis and optic disc swelling. The optic foramina were of normal size on skull radiographs and no abnormalities were noted on ventriculography; however, the level of the intracranial pressure (ICP) was not documented. Alkaline phosphatase was elevated at 475 U/l. A cranial vault expansion combined with bilateral orbital decompressions was performed with resolution of the proptosis and disc oedema.

The patient developed slowly progressive, profound bilateral sensorineural deafness from the age of 22. Tomography of the petrous temporal bones demonstrated severe stenosis of both internal auditory meati.

The patient underwent unsuccessful trials of medical therapy, firstly with calcitonin in 1974 and subsequently with the biphosphonate etidronate in 1982. Her bone pain remains well controlled on prednisolone 10 mg daily. In 1983 the patient developed a left sided corneal abscess secondary to upper lid entropion which required surgical correction.

She subsequently presented to the Institute of Neurological Sciences in Glasgow in January 1988 with bilateral visual blurring and ocular irritation.

On examination, the typical facial features associated with PDD were modified by her previous craniofacial surgery and the effects of long term systemic steroid therapy (Fig 8). Visual acuities were 6/18 right and 6/24 left. The visual field of the right eye was full; the visual field of the left eye was constricted nasally. Minimal lower motor neuron facial nerve weakness with intact Bell’s phenomenon was present bilaterally. There was evidence of chronic exposure keratopathy with superficial punctate erosions and inferior corneal neovascularisation, more marked on the left side. Both optic discs appeared minimally pale but within normal limits. Diagnostic syringing confirmed the presence of bilateral nasolacrimal duct blockage which was probably secondary to a combination of her mid facial hypoplasia and an osteosclerotic stenosis of the nasolacrimal duct.

Skull radiography demonstrated diffuse osteosclerotic changes in addition to the tanta-
lum plates which had been inserted as part of the previous cranial expansion (Fig 9). The lesser wings of the sphenoid bone appear unusually prominent as both the vertical and orbital portions of the frontal bone have been removed as part of the orbital decompression. An axial CT scan demonstrated diffuse thickening of the bones of the vault and base of the skull, bone defects were noted in the roof of both orbits (Fig 10).

Bilateral lateral tarsorrhaphies were performed, and ocular lubricants were continued. Despite initial improvement, over a 2 year period the patient developed recurrent left corneal ulceration with corneal decompensation and with formation of a descemetocele. At the last ophthalmic consultation in May 1997 the visual acuities were 6/9 and counting fingers with minimal peripheral constriction of the visual fields.

**Results**

All three patients had bilateral optic disc swelling with no radiological evidence of either compressive optic neuropathy or thrombosis of the intracranial venous sinuses. The aetiology of the disc swelling was proved to be papilloedema in the first two cases and was probably the dominant cause in the third case. The papilloedema resolved spontaneously in the second case and after treatment with acetazolamide in the first case.

**Discussion**

**AETIOLOGY OF RAISED INTRACRANIAL PRESSURE**

The aetiology of raised ICP in patients with PDD is probably multifactorial. Skull base involvement with stenosis of the jugular foramina has been demonstrated on MR scanning, and angiography has demonstrated distortion of the intracranial vessels. Both abnormalities are considered to be indirect evidence of impairment of venous drainage. Neuroimaging failed to demonstrate evidence of sagittal or lateral sinus thrombosis in our patients. Encroachment of the cranial contents by progressive thickening of the calvarial bone may contribute to the raised ICP; however, we observed no effacement of the ventricles on CT or MRI.
Most reports of benign intracranial hypertension (BIH) occurring in association with systemic corticosteroid treatment have concerned young children, although there have been reported cases involving adults. The onset of BIH usually occurs on withdrawal of corticosteroids after prolonged treatment; however, several reports exist of BIH occurring during their use. The dose of prednisolone taken by our first patient had remained stable before her presentation with papilloedema. Our second patient experienced relapses of his papilloedema many years after stopping corticosteroid treatment and our third patient was not taking corticosteroids when she developed disc swelling. This suggests that in the two patients in whom the ICP was measured, the episodes of raised ICP were unrelated to the use or withdrawal of systemic corticosteroids.

The spontaneous remissions of the elevated ICP in the second patient are difficult to explain but probably reflect autoregulatory mechanisms. These affect the balance between CSF production and absorption which can overcome the compressive effects associated with bony enlargement of the skull. In at least two of our cases, the episodes of raised ICP seem to have been temporally related to elevations of serum alkaline phosphatase, indicating an exacerbation of the bony dysplasia and suggesting a causal relation.

AETIOLOGY OF VISUAL FAILURE
In all previous reported cases of visual failure associated with PDD,10 11 17 18 with possibly one exception,19 the aetiology of the visual loss has been assumed to have occurred solely as a result of a compressive optic neuropathy. PDD is part of the spectrum of primary bone disorders which include craniofacial dysplasia, fibrous dysplasia, osteopetrosis, and aneurysmal bone cysts, all of which have been reported to cause progressive stenosis of the optic canals.20 22 Although raised ICP has been described in patients with PDD in whom visual loss has occurred, the elevation of ICP in those patients has been thought to be either non-contributory17 or only partially responsible4 for the accompanying visual loss.

Yen et al17 reported a patient who underwent a successful combined bilateral orbital and optic canal decompression and who was incidentally found to have elevated ICP (23 cm of water preoperatively and 28 cm postoperatively). As with other disorders of bone metabolism, papilloedema can either cause visual loss or coexist with a compressive optic neuropathy and appear to cause visual loss. Van Dalsem et al14 reported a case in which optic nerve compression and papilloedema coexisted; both were thought to contribute to the visual impairment.

The occurrence of peripheral and paracentral visual field constriction with preservation of colour vision and acuity suggests that the dominant cause of the acute visual loss observed in our patients is secondary to papilloedema rather than a compressive optic neuropathy which tends to reduce central acuity and colour vision early.

Both the first and second of our cases had papilloedema with no radiological or clinical evidence of a compressive optic neuropathy. The disc swelling resolved spontaneously in the second case and following treatment with acetazolamide in the first case.

Our third patient was thought to have significant bony encroachment of the cranial cavity, with no radiological evidence of optic canal stenosis. As the disc swelling resolved after a combined cranial vault expansion and orbital decompression procedure, it would seem likely that the visual failure she experienced in childhood was at least in part secondary to raised ICP.

TREATMENT OPTIONS
Persistently raised ICP occurring in association with progressive deterioration in visual function is an indication for aggressive treatment; however, both CSF shunting procedures and optic nerve sheath fenestration can fail over time. Based upon the long term success obtained in our last patient and that reported following subtemporal decompression,4 13 we believe that some type of cranial vault expansion procedure, possibly combined with an orbital decompression, would be worthy of consideration in these patients.

Surgical intervention in PDD is not straightforward. The results of combined orbital and optic canalicular decompression have been reported in two patients. However, tomography of the optic canals and orbital roofs performed 8 months to 1 year postoperatively demonstrated complete reconstitution of the surgically resected bone.16 17 Interestingly, the skull radiographs and CT scans of our third patient demonstrated a lack of bony regrowth following the removal of both the vertical and orbital portions of the frontal bone as part of the orbital decompression performed 31 years earlier.

Regardless of whether or not surgical intervention is indicated in patients with PDD, the definitive treatment of such patients is likely to rest in the long term control of the abnormal formation of bone. The administration of systemic corticosteroids has been shown to decrease the abnormally high diaphyseal uptake of 99m-technetium methylene diphosphonate, which is thought to represent focal osteoblastic overactivity.23 Steroids are also effective in alleviating limb pain and muscle weakness and improve the quality of life although not necessarily altering the course of the disease.24 Biphosphonates such as disodium etidronate are adsorbed onto hydroxyapatite crystals reducing their rate of growth and dissolution and retarding the mineralisation of osteoid and therefore, the rate of bone turnover. Our third patient failed to benefit symptomatically, biochemically, or radiologically from a 4 month therapeutic trial of etidronate. The only other report of the use of this drug in PDD is limited to one case report in which the elevation in alkaline phosphatase activity was reduced but not normalised after 7 weeks of treatment.25 Calcitonin has been used to treat the bone pain and neurological
complications of Paget’s disease, but we are unaware of any reports of its use in patients with PDD. Neither our first nor our third patient improved after short therapeutic trials of calcitonin.

In summary, the visual loss documented in at least two of the three patients described above appears to be solely attributable to raised ICP. Normalisation of the ICP has led to an improvement and stabilisation of the visual function in all three patients.

We thank the three patients for permission to report their cases.